PinealonvsSelank

Pinealon is a short tripeptide (Glu-Asp-Arg) belonging to the Khavinson family of peptide bioregulators — small peptides hypothesised to regulate gene expression in tissue-specific ways by binding directly to DNA promoter regions. Pinealon is the brain- and pineal-gland-targeted member of this family, designed to penetrate cells and the nuclear membrane to interact with promoter sequences of genes involved in neuronal function and circadian regulation.

Proposed mechanisms include modulation of melatonin synthesis pathways (via effects on pineal gland function), upregulation of antioxidant defence enzymes in neurons, and protection against oxidative stress from age-related accumulation of reactive oxygen species. Russian preclinical studies have reported pinealon-induced increases in expression of genes involved in serotonin and melatonin metabolism, neurotrophic factor signalling, and antioxidant capacity, alongside protective effects against neurotoxin-induced neuronal damage in animal models.

The extremely short plasma half-life (around 30 minutes) is a feature shared with all Khavinson tripeptides — the proposed model is that the peptides act as transient signalling molecules that trigger longer-lasting changes in gene expression, with effects persisting well beyond plasma clearance. This model would explain the use of pulse-dosing protocols (10-30 day courses repeated periodically) rather than continuous administration. Importantly, almost all published efficacy data comes from Russian research groups associated with the original Khavinson laboratory, and the bioregulator framework has not been independently validated in Western clinical settings. Mechanistic claims should be treated as preliminary, and clinical use remains largely anecdotal outside Russia.

Selank is a synthetic heptapeptide based on the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with a stabilizing Pro-Gly-Pro extension at the C-terminus that dramatically increases its resistance to aminopeptidase degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it was designed to combine the immune-enhancing effects of tuftsin with anxiolytic and nootropic properties.

The anxiolytic mechanism involves modulation of GABAergic neurotransmission. Selank acts as an allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA in anxiety-related brain regions including the amygdala, hippocampus, and prefrontal cortex. This produces a benzodiazepine-like anxiolytic effect without the sedation, cognitive impairment, or addiction potential associated with benzodiazepines — because Selank modulates rather than directly activates the receptor. Additionally, Selank stabilizes enkephalins (endogenous opioid pentapeptides) by inhibiting enkephalin-degrading enzymes (aminopeptidases and enkephalinase/neprilysin), prolonging their mood-regulating and anxiolytic signaling.

The nootropic effects are mediated through neurotrophic factor upregulation. Selank increases expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex, promoting dendritic branching, synaptic plasticity, and long-term potentiation — the cellular mechanisms underlying memory formation and cognitive flexibility. It also modulates serotonergic (5-HT) metabolism, altering the balance between serotonin and its metabolite 5-HIAA in key brain regions. The immunomodulatory component derives from the tuftsin core: tuftsin naturally activates monocytes and macrophages through specific receptors, enhancing phagocytic activity and modulating IL-6, TNF-α, and other cytokine production. This immune regulation occurs at sub-anxiolytic doses, suggesting it is an independent pharmacological effect. The combined anxiolytic, cognitive-enhancing, and immunomodulatory profile is unique among available peptides.